<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03654482</url>
  </required_header>
  <id_info>
    <org_study_id>2016_018</org_study_id>
    <nct_id>NCT03654482</nct_id>
  </id_info>
  <brief_title>SuperSeton Pilot Studie</brief_title>
  <official_title>Pilot Study of SuperSeton Placement in Patients With Perianal Fistulas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Proctos Kliniek</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MediShield B.V.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Delft University of Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Perianal fistulas are a common incapacitating problem. Many patients are treated
      by seton drainage to prevent recurrent abscess formation. Nowadays, vessel loops or sutures
      are used for drainage. The knot of these seton drains can cause complaints of pain or
      tenderness if it presses against the external opening of the fistula or even slides in to the
      fistula tract. Medishield B.V. designed a knotless seton drain, the SuperSeton. This could
      decrease the pain complaints caused by the knot.

      Objective: The aim of this study is to determine the feasibility of SuperSeton placement in
      patients with perianal fistulas.

      Study design: The design of the study is a feasibility study.

      Study population: Patients (≥ 18 years) with perianal fistulas (ever) treated with a knotted
      seton are eligible.

      Intervention: The SuperSeton will be placed at the outpatient clinic in patients that already
      have a seton in situ. This seton will then be exchanged by the SuperSeton. In case patients
      do not have a seton in situ, the SuperSeton can be placed at the operating theatre in day
      care setting instead of a regular seton.

      Main study parameters/endpoints: The primary outcome is seton failure (loosening of the
      seton). Secondary outcomes are time of procedure, complications and quality of life measured
      by the PDAI ('Perianal Disease Activity Index').

      Nature and extent of the burden and risks associated with participation: The SuperSeton will
      be placed in patients with perianal fistulas (ever) treated with a conventional knotted
      seton. There are no additional risks involved. The seton will be placed at the outpatient
      clinic in patients with a seton in situ, or at the operating theatre in day care setting in
      patients with a perianal abscess without a seton. The material that is used for the Setons is
      of medical grade polyurethane, this is the same material of catheters that are already used
      in clinical practice (instech BTPU 027). The Setons including the insert (BTPU) are supplied
      sterile (Synergy Health). Sample size calculation: A group of 60 patients will be included to
      determine feasibility of the SuperSeton. The proposed treatment protocol is considered
      feasible if at least 70% of the SuperSetons stay in place.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 10, 2016</start_date>
  <completion_date type="Actual">July 4, 2018</completion_date>
  <primary_completion_date type="Actual">July 4, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seton failure</measure>
    <time_frame>3 months</time_frame>
    <description>Loosening of the seton</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Perianal Disease Activity Index score</measure>
    <time_frame>3 months</time_frame>
    <description>The PDAI is the gold standard for evaluating the severity of perianal disease. It includes five items: discharge, pain, restriction of sexual activity, type of perianal disease, and degree of induration. Each category is graded on a five-point Likert scale ranging from no symptoms to severe symptoms. The sum of the five subscores represents the total PDAI score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure time</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing complications</measure>
    <time_frame>3 months</time_frame>
    <description>Number of participants experiencing peri-operative complications, an increase in perianal pain complains, and perianal abscesses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants requiring surgical re-interventions</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Perianal Fistula</condition>
  <condition>Perianal Crohn Disease</condition>
  <arm_group>
    <arm_group_label>SuperSeton arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SuperSeton</intervention_name>
    <description>The SuperSeton will be placed at the outpatient clinic in patients that already have a seton in situ. This seton will then be exchanged by the SuperSeton. In case patients do not have a seton in situ, the SuperSeton can be placed at the operating theatre in day care setting instead of a regular seton.</description>
    <arm_group_label>SuperSeton arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 18 years

          -  Written informed consent

          -  Perianal fistula with a seton in situ or a recurrent perianal fistula for which a new
             seton will be placed

        Exclusion Criteria:

          -  Patients with a pacemaker or an ICD in situ

          -  Rectovaginal fistula

          -  Patients with a stoma

          -  Life expectancy &lt; 2 years

          -  The inability of reading/understanding and filling in the questionnaires

          -  Dementia or altered mental status that would prohibit the understanding and giving of
             informed consent

          -  Participation in another trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 15, 2018</study_first_submitted>
  <study_first_submitted_qc>August 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2018</study_first_posted>
  <last_update_submitted>August 29, 2018</last_update_submitted>
  <last_update_submitted_qc>August 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>Prof. dr. W.A. Bemelman</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Knotless seton</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Perianal Disease Activity Index</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Fistula</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 16, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/82/NCT03654482/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

